In November 2019, the Centers for Medicare & Medicaid Services (CMS) finalized significant changes to the Medicare Physician Fee schedule.1 As part of this update, CMS announced that, for the first time, the agency would begin implementing a prior authorization (PA) requirement in 2020 for 5 new procedures relevant to the field of facial plastic and plastic surgery: blepharoplasty, botulinum toxin injections, panniculectomy, rhinoplasty, and vein ablation. These particular procedures were targeted owing to the significantly increased number of these services submitted as claims compared with the expected number, based on the number of Medicare beneficiaries. Herein, we examine the new policy and its implications to the field of facial plastic and reconstructive surgery, oculoplastic surgery, and plastic surgery.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Gadkaree SK, Rathi VK, Hadlock T. CMS Adoption of Prior Authorization Requirements—Implications for Facial Plastic Surgery. JAMA Otolaryngol Head Neck Surg. 2020;146(5):397–398. doi:10.1001/jamaoto.2020.0235
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: